New Hampshire Patent of the Month – March 2025
Adimab, LLC has secured U.S. Patent No. 12,258,679 for its innovative method titled “Polyclonal mixtures of antibodies, and methods of making and using them.” This advancement promises to enhance antibody therapies by broadening their target range and improving immune responses.
Expanding Antibody Diversity
Traditional monoclonal antibodies focus on a single epitope, which can limit their effectiveness against complex antigens. Adimab’s patented approach addresses this by generating polyclonal antibody mixtures through iterative selection processes. By exposing antigens to diverse antibody libraries and selecting for high-affinity binders, the method produces a comprehensive antibody repertoire.
This technique allows for the creation of antibody mixtures that can target multiple epitopes on an antigen, potentially leading to more robust therapeutic effects. Such diversity is particularly beneficial in treating diseases where pathogens or cancer cells exhibit high variability.
Implications for Therapeutic Development
The ability to produce tailored polyclonal antibodies opens new avenues in therapeutic development. These mixtures can offer enhanced efficacy and reduced resistance compared to monoclonal therapies. Adimab’s method could accelerate the development of treatments for complex diseases, including various cancers and infectious diseases.
By refining antibody diversity and selection, Adimab continues to lead in antibody engineering, providing tools that may significantly impact future therapeutic strategies.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
